Renal function in gout: Long-term treatment effects of febuxostat

Journal of Clinical Rheumatology

Volumn 17, Issue 1, 2011, Pages 7-13

  Whelton, Andrew ^a   MacDonald, Patricia A ^b   Zhao, Lin ^b   Hunt, Barbara ^b   Gunawardhana, Lhanoo ^c  

^a Universal Clinical Research Center Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

Author keywords

allopurinol; febuxostat; Gout; hyperuricemia; renal function

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSESTHESIA; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GOUT; HEADACHE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERURICEMIA; INFLUENZA; KIDNEY DISEASE; KIDNEY FUNCTION; LIMB INJURY; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MENTAL DISEASE; MUSCULOSKELETAL PAIN; NEUROLOGIC DISEASE; PARESTHESIA; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; KIDNEY; MALE; MIDDLE AGED; THIAZOLES; YOUNG ADULT;

EID: 78651373138     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318204aab4     Document Type: Article

References (52)

1. Pillinger MH, Rosenthal P, Abeles AM. Hyperuricemia and gout: new insights into pathogenesis and treatment Bull NYU Hosp Jt Dis. 2007;65:215-221.
2. Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection ofrenal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691-697.
3. Chen YC, Su CT, Wang ST, et al. A preliminary investigation of the association between serum uric acid and impaired renal function. Chang Gung Med J. 2009;32:66-71.
4. Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression ofrenal disease. Semin Nephrol. 2005;25:43-49.
5. Avram Z, Krishnan E. Hyperuricaemia\where nephrology meets rheumatology. Rheumatology (Oxford). 2008;47:960-964.
6. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642-650.
7. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001;161:1207-1216.
8. Johnson RJ, Feig DI, Nakagawa T, et al. Pathogenesis ofessential hypertension: historical paradigms andmodern insights. JHypertens. 2008;26:381-391.
9. Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49:298-303.
10. Panoulas VF, Douglas KM, Milionis HJ, et al. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. JHum Hypertens. 2007;46:1466-1470.
11. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
13. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005; 16:791-799.
14. Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2407-2413.
15. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-1324.
16. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925-934.
17. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci. 2005;76:1835-1847.
18. US Food and Drug Administration. Center for Drug Evaluation and Research. New Drug Approval for Uloric. Available at: www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory#apphist. Accessed December 20, 2009.
19. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complexandmechanismof inhibition. J Biol Chem. 2003;278:1848-1855.
20. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-2461.
21. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-1548.
22. Uloric Full Prescribing Information. Deerfield, IL: Takeda Pharmaceuticals North America, Inc; 2009.
23. Becker M, Schumacher HR, Espinoza L, et al. The urate-lowering efficacy and safety of febuxostat for the treatment of hyperuricemia and gout. Arthritis Res Ther. 2010;12:R63.
24. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-1106.
25. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression ofrenal disease. J Am Soc Nephrol. 2002;13:2888-2897.
26. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991-F997.
27. Eraranta A, Kurra V, Tahvanainen AM, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency J Hypertens. 2008;26:1661-1668.
28. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67:237-247.
29. Sanchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008;23:1179-1185.
30. Sanchez-Lozada LG, Tapia E, Soto V, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol. 2008;108:69-78.
31. Gibson T, Rodgers V, Potter C, et al. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis. 1982;41:59-65.
32. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39:1227-1233.
33. Siu YP, Leung KT, Tong MK, et al. Use ofallopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-59.
34. Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976;31:155-163.
35. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52:916-923.
36. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48:188-194.
37. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout Arthritis Rheum. 1977;20:895-900.
38. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
39. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
40. Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002;47:610-613.
41. Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem. 2008;283:26834-26838.
42. Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 2008;5:e197.
43. Graessler J, Graessler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum. 2006;54:292-300.
44. Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet. 2008;372:1953-1961.
45. Myllymaki J, Honkanen T, Syrjanen J, et al. Uric acid correlates with the severity ofhistopathological parameters in IgA nephropathy. Nephrol Dial Transplant. 2005;20:89-95.
46. Obermayr RP, Temml C, Knechtelsdorfer M, et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant. 2008;23:1265-1273.
47. Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008;295:F1134-F1141.
48. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and notby lowering uric acid. Circulation. 2006;114:2508-2516.
49. McCarthy GM, Barthelemy CR, Veum JA, et al. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum. 1991;34:1489-1494.
50. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356-360.
51. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007;27:435-440.
52. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003;17:397-414.